March 2026 Quarterly Activities Report and Appendix 4C
Filed with ASX · · 9 pages · English
Summary by 6ix AI
The report highlights the signing of a Memorandum of Understanding with Tezcat Biosciences to enhance collaboration on drug delivery systems. Additionally, Dr. Olivier Laczka has been appointed as the new CEO, focusing on the Sofra RNA program. The financial update indicates a positive cash flow from operating activities and ongoing efforts to secure additional capital.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Noxopharm
- Positive SOF-SKN dosing data shows prolonged skin retention
- Noxopharm appoints Dr Olivier Laczka as new CEO
- Resignation of Chief Executive Officer
- Appendix 4D and FY2026 Half Year Financial Report
- R&D rebate strengthens cash position
Later from Noxopharm
- Innovative collaboration further expands Sofra platform
- New data shows SOF-SKN active ingredient efficacy
- Noxopharm progresses US regulatory strategy
- Noxopharms Sofra assets to be presented at global conference
- New data confirms cancer-fighting potential
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm